secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001140361-24-036940
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech Q2 net loss narrows to $8.3M; FDA aligned on Phase 3 trial for Versamune HPV in HNSCC
--------------------------------------------------------------------------------

- Net loss $8.3M ($0.23/share) vs $11.5M ($0.37/share) YoY; R&D expenses down 44% to $4.5M.
- Cash and equivalents $57.7M as of June 30, 2024.
- FDA alignment achieved on Phase 3 VERSATILE-003 trial design for Versamune HPV + pembrolizumab; start Q4 2024.
- Updated VERSATILE-002 data shows median OS of 30 months; abstracts accepted at ESMO, ASTRO, ICIS 2024.
- Total operating expenses reduced to $8.7M from $12.7M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124036940/0001140361-24-036940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124036940/ef20034030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer